What is in the pipeline for new treatments for bladder pain syndrome/ interstitial cystitis?

Curr Opin Urol. 2024 Mar 1;34(2):58-63. doi: 10.1097/MOU.0000000000001159. Epub 2024 Jan 3.

Abstract

Purpose of review: Despite available treatments, many bladder pain syndrome/interstitial cystitis (BPS/IC) patients continue to have poor quality of life. Thus, there is an urge for new therapies. Our manuscript aims to review papers about BPS/IC treatments published in the last 2 years.

Recent findings: During this period, several treatments were tested, most of them new and others combining treatments already used. Pentosan polysulfate, interleukin 1 antagonist, low energy shock wave, physical therapy, hypnosis, acupuncture, clorpactin, dimethyl sulfoxide and hyaluronic acid plus botulinum toxin-A showed positive results. ASP3652 and lidocaine-releasing intravesical systems failed to prove their efficacy.

Summary: Validation of these studies is arduous due to the broad spectre of BPS/IC phenotypes, small number of patients enrolled, distinct outcome measures and short-term follow-up. It is also important to highlight that some authors combined therapies, and others split central and peripheric phenotypes before treatment. Therefore, soon, phenotyping and combining therapies with a step-by-step approach will be needed in BPS/IC treatment.

Publication types

  • Review

MeSH terms

  • Administration, Intravesical
  • Botulinum Toxins, Type A* / therapeutic use
  • Cystitis, Interstitial* / drug therapy
  • Humans
  • Lidocaine / therapeutic use
  • Quality of Life

Substances

  • Botulinum Toxins, Type A
  • Lidocaine